Michael A Pfaller

Summary

Affiliation: JMI Laboratories
Country: USA

Publications

  1. pmc In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds
    Michael A Pfaller
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 51:2608-16. 2013
  2. pmc Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic
    Michael A Pfaller
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 51:2571-81. 2013
  3. pmc Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata
    M A Pfaller
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 50:1199-203. 2012
  4. pmc Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    J Clin Microbiol 49:3800-4. 2011
  5. pmc Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 55:561-6. 2011
  6. pmc In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 55:5155-8. 2011
  7. doi request reprint Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 68:858-63. 2013
  8. pmc Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:352-7. 2012
  9. pmc Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 54:2655-9. 2010
  10. doi request reprint Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 38:65-9. 2011

Detail Information

Publications31

  1. pmc In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds
    Michael A Pfaller
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 51:2608-16. 2013
    ..Isavuconazole demonstrates broad-spectrum activity against this global collection of opportunistic fungi, and the CLSI and EUCAST methods can be used to test this agent against Candida, with highly comparable results. ..
  2. pmc Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic
    Michael A Pfaller
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 51:2571-81. 2013
    ..Overall, echinocandin and triazole resistance rates were low; however, the fluconazole and echinocandin coresistance among C. glabrata strains warrants continued close surveillance. ..
  3. pmc Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata
    M A Pfaller
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 50:1199-203. 2012
    ..glabrata tested in 2001 to 2004. These data document the broad emergence of coresistance over time to both azoles and echinocandins in clinical isolates of C. glabrata...
  4. pmc Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    J Clin Microbiol 49:3800-4. 2011
    ..2]), and VRC (0.25 [98.2]). In the absence of species-specific CBP values, these WT MIC distributions and ECVs will be useful for monitoring the emergence of reduced susceptibility to the triazole and echinocandin antifungals...
  5. pmc Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 55:561-6. 2011
    ..Although resistance to the azoles and echinocandins remains uncommon among CO isolates, we demonstrate the emergence of nosocomial occurrences of C. glabrata expressing resistance to both monitored classes of antifungal agents...
  6. pmc In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 55:5155-8. 2011
    ..terreus SC (MEC, 0.015 μg/ml). In conclusion, E1210 was a very potent and broad-spectrum antifungal agent regardless of in vitro method applied, with excellent activity against AMB-R and itraconazole-R strains of Aspergillus spp...
  7. doi request reprint Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 68:858-63. 2013
    ..using CLSI and EUCAST broth microdilution (BMD) methods...
  8. pmc Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:352-7. 2012
    ..and Scedosporium spp. Furthermore, in vitro susceptibility testing of E1210 against isolates of Fusarium and Scedosporium may be accomplished using either of the CLSI or EUCAST BMD methods, each producing very similar results...
  9. pmc Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 54:2655-9. 2010
    ..Furthermore, results from this large, geographically diverse Candida spp. collection demonstrated that fks1 HS1 mutations remain uncommon among isolates with various echinocandin MIC levels...
  10. doi request reprint Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 38:65-9. 2011
    ..Concern regarding C. glabrata must now include resistance to echinocandins as well as azole antifungal agents...
  11. doi request reprint Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Mycopathologia 174:259-71. 2012
    ..Molecular confirmation of fungal identification is essential in epidemiological surveys such as SENTRY...
  12. pmc In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods
    Michael A Pfaller
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 57:1065-8. 2013
    ..3%. MK-3118 was determined to be a potent agent regardless of the in vitro method applied, with excellent activity against contemporary wild-type and itraconazole-resistant strains of Aspergillus spp...
  13. doi request reprint In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 71:167-70. 2011
    ..008-0.06 μg/mL), and was the most potent agent tested against caspofungin-resistant strains of C. albicans (MIC range, 0.008-0.12 μg/mL), C. glabrata (MIC range, 0.03-0.06 μg/mL), and C. tropicalis (MIC range, 0.015-0.06 μg/mL)...
  14. ncbi request reprint Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000)
    Jeffrey T Kirby
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 43:303-9. 2002
    ..pneumoniae) was documented in all three monitored regions (Latin America > Europe > North America). Continued development of garenoxacin as a treatment of pathogens that commonly cause SSTIs appears to be warranted...
  15. pmc Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, Iowa 52317, USA
    J Clin Microbiol 49:396-9. 2011
    ..5%), and C. albicans isolates were more common in APAC (56.9%), with C. parapsilosis (25.6%) and C. tropicalis (17.0%) being more prominent in LAM. Emerging resistance patterns among C. glabrata cases in NAM require focused surveillance...
  16. doi request reprint Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimi
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 69:45-50. 2011
    ..fumigatus. Overall, echinocandin and triazole resistance rates were minimal; however, the distinct increase in echinocandin resistance observed among C. glabrata strains warrants further surveillance associated with molecular support...
  17. ncbi request reprint Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections
    Michael A Pfaller
    CAST Laboratories, University of Iowa College of Medicine, Iowa City, Iowa, USA
    Diagn Microbiol Infect Dis 44:77-84. 2002
    ..catarrhalis in CARTI, and high fluoroquinolone potency/spectrum (>97% susceptible). beta-lactams and macrolides continue to be compromised by increasing resistances in pathogens isolated in these monitored primary care settings...
  18. doi request reprint Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009)
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 68:278-83. 2010
    ..Cg BSI isolates may show lower susceptibility rates to both azoles and echinocandins with the highest rates of resistance detected in 20- to 59-year-old patients...
  19. doi request reprint Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 66:2581-4. 2011
    ..To compare European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI broth microdilution (BMD) methods for testing the novel antifungal E1210 against a recent collection of 102 clinical isolates of Candida spp...
  20. pmc Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus
    Ronald N Jones
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Clin Microbiol 48:972-6. 2010
    ..7% +/- one log2 dilution. The diagnostic susceptibility testing reagents (including Etest) for fusidic acid (CEM-102) performed at an excellent level of intermethod agreement for the proposed breakpoint criteria...
  21. pmc Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance pro
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 51:117-24. 2013
    ..famata in fungal infections is much lower than previously appreciated and that commercial systems do not produce accurate identifications except for the newly introduced MALDI-TOF instruments...
  22. pmc Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 58:577-80. 2014
    ..Mutations that have been reported to decrease the echinocandin binding to the 1,3-β-d-glucan synthase were categorized as resistant by applying the new CLSI breakpoint criteria for all three echinocandins. ..
  23. ncbi request reprint Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp
    Michael A Pfaller
    JMI Laboratories, North Liberty, Iowa Electronic address
    Diagn Microbiol Infect Dis 79:198-204. 2014
    ....
  24. ncbi request reprint Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000)
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 43:239-43. 2002
    ..In all regions, aminoglycosides in combination with carbapenems, cefepime, or piperacillin/tazobactam would provide more potential antipseudomonal activity than fluoroquinolone combinations for wide-spectrum empiric regimens...
  25. pmc Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria
    Michael A Pfaller
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 52:108-14. 2014
    ..glabrata, 80% of the C. glabrata mutants were non-WT for both agents (96% concordance). Micafungin may serve as an acceptable surrogate marker for the prediction of susceptibility and resistance of Candida to caspofungin. ..
  26. doi request reprint AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States
    Michael A Pfaller
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 55:S187-93. 2012
    ....
  27. doi request reprint Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 65:2396-404. 2010
    ....
  28. ncbi request reprint Ciprofloxacin as broad-spectrum empiric therapy--are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?
    Ronald N Jones
    The JONES Group and JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 42:213-5. 2002
    ..Local susceptibility testing data must be assessed before fluoroquinolone empiric therapy can be used with confidence...
  29. doi request reprint Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011)
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 78:422-8. 2014
    ..coli and K. pneumoniae). In summary, ceftaroline showed potent activity against a large contemporary collection (6222) of bacterial isolates associated with ABSSSI in the USA. ..
  30. pmc Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: initial development of in vitro susceptibility test methods
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    J Clin Microbiol 40:461-5. 2002
    ....
  31. pmc Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004-2008
    Michael A Pfaller
    JMI Laboratories, North Liberty, Iowa, United States of America Department of Pathology, University of Iowa, Iowa City, Iowa, United States of America
    PLoS ONE 9:e101510. 2014
    ..The variability in species distribution in these centers underscores the importance of local epidemiology in guiding the selection of antifungal therapy. ..